The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

The use of BTKi and BCL-2 inhibitors as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has significantly transformed the treatment landscape of relapsed/refractory disease.

Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.

Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

Educating clinicians about the recent clinical advances is essential since this will aid in making informed clinical decisions to optimize the treatment for relapsed/refractory CLL/SLL.

This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.